Old Web
English
Sign In
Acemap
>
authorDetail
>
Ting-Fang Kung
Ting-Fang Kung
Taipei Veterans General Hospital
Internal medicine
Lenvatinib
Oncology
Leiomyosarcoma
Pathology
2
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER).
2020
Journal of Clinical Oncology
Tom Wei-Wu Chen
Chih-Wei Yu
Ruey-Long Hong
Chueh-Chuan Yen
Jhe-Cyuan Guo
San-Chi Chen
Jen-Chieh Lee
Mei-Lu Chen
Hsin-Fang Chang
Meng-Chi Hsu
Ting-Fang Kung
Show All
Source
Cite
Save
Citations (1)
The phase Ib result of the safety and efficacy of lenvatinib (lenv) plus eribulin (eri) in advanced adipocytic sarcoma (LPS) and leiomyosarcoma (LMS): LEADER study (NCT03526679).
2019
Journal of Clinical Oncology
Tom Wei-Wu Chen
Ruey-Long Hong
Chueh-Chuan Yen
San-Chi Chen
Jhe-Cyuan Guo
Meng-Chi Hsu
Ting-Fang Kung
Show All
Source
Cite
Save
Citations (0)
1